Aerovate Therapeutics, Inc. (AVTE)
NASDAQ
Market Cap
$74.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
120 of 963
Rank in Industry
84 of 552
Largest Insider Buys in Sector
AVTE Stock Price History Chart
AVTE Stock Performance
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Activity of Aerovate Therapeutics, Inc.
Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $6.81M worth of Aerovate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $46.5M.
The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.
List of Insider Buy and Sell Transactions, Aerovate Therapeutics, Inc.
| 2024-06-17 | 928,110 0.2418% | $1.67 | $1.55M | +20.61% | ||||
| 2024-06-14 | Sale | SEE REMARKS | 15,000 0.0586% | $25.03 | $375,450 | -91.92% | ||
| 2024-06-14 | Sale | CHIEF TECHNICAL OFFICER | 10,600 0.0413% | $25.00 | $265,000 | -91.92% | ||
| 2024-06-13 | Sale | CHIEF MEDICAL OFFICER | 6,000 0.0229% | $24.50 | $147,000 | -91.90% | ||
| 2024-05-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0136% | $21.08 | $84,332 | -89.94% | ||
| 2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0347% | $21.58 | $215,755 | -90.51% | ||
| 2024-05-02 | Sale | CHIEF TECHNICAL OFFICER | 1,981 0.007% | $21.02 | $41,631 | -89.47% | ||
| 2024-05-01 | Sale | CHIEF EXECUTIVE OFFICER | 11,357 0.0386% | $20.34 | $230,946 | -89.32% | ||
| 2024-04-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0143% | $22.38 | $89,522 | -89.21% | ||
| 2024-04-17 | Sale | SEE REMARKS | 6,853 0.0245% | $22.37 | $153,327 | -89.21% | ||
| 2024-04-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0375% | $24.70 | $246,971 | -89.63% | ||
| 2024-04-10 | Sale | SEE REMARKS | 7,500 0.0268% | $26.85 | $201,392 | -90.56% | ||
| 2024-04-09 | Sale | director | 11,882 0.0428% | $28.15 | $334,478 | -90.89% | ||
| 2024-04-01 | Sale | SEE REMARKS | 12,495 0.0455% | $31.23 | $390,208 | -91.50% | ||
| 2024-04-01 | Sale | SEE REMARKS | 3,325 0.0124% | $31.97 | $106,317 | -91.50% | ||
| 2024-04-01 | Sale | CHIEF TECHNICAL OFFICER | 5,300 0.0181% | $29.19 | $154,697 | -91.50% | ||
| 2024-04-01 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.035% | $30.00 | $300,033 | -91.50% | ||
| 2024-03-28 | Sale | CHIEF MEDICAL OFFICER | 9,000 0.0322% | $29.50 | $265,500 | -91.17% | ||
| 2024-03-27 | Sale | SEE REMARKS | 11,068 0.0393% | $27.97 | $309,519 | -90.79% | ||
| 2024-03-25 | Sale | SEE REMARKS | 3,432 0.0129% | $28.01 | $96,119 | -90.24% |
Insider Historical Profitability
<0.0001%
| RA CAPITAL MANAGEMENT, L.P. | 7893678 27.3379% | $2.59 | 2 | 0 | <0.0001% | |
| GRAYZEL DAVID S. | director | 14502 0.0502% | $2.59 | 1 | 1 | <0.0001% |
| Gillies Hunter | CHIEF MEDICAL OFFICER | 5602 0.0194% | $2.59 | 0 | 15 | |
| Eldridge George A | SEE REMARKS | 5022 0.0174% | $2.59 | 0 | 21 | |
| NIVEN RALPH | CHIEF SCIENTIFIC OFFICER | 1609 0.0056% | $2.59 | 0 | 19 | |
| Dake Benjamin T | SEE REMARKS | 1291 0.0045% | $2.59 | 0 | 51 | |
| NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 0 0% | $2.59 | 0 | 21 | |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | 0 0% | $2.59 | 0 | 8 | |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 3758686 13.0173% | $2.59 | 1 | 0 | <0.0001% |
| Katabi Maha | 3758686 13.0173% | $2.59 | 1 | 0 | <0.0001% | |
| Atlas Venture Fund XII, L.P. | 10 percent owner | 3103879 10.7496% | $2.59 | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2030691 7.0328% | $2.59 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $244.37M | 28.69 | 8.26M | 0% | +$0 | 0.25 | |
| Sofinnova | $111.14M | 13.05 | 3.76M | 0% | +$0 | 0.23 | |
| Tcg Crossover Management Llc | $65.09M | 7.64 | 2.2M | 0% | +$0 | 0.1 | |
| Atlas Venture Life Science Advisors Llc | $60.3M | 7.08 | 2.04M | 0% | +$0 | 5.6 | |
| Baker Bros Advisors LP | $49.69M | 5.83 | 1.68M | 0% | +$0 | 0.36 | |
| Frazier Life Sciences Management L P | $35.63M | 4.18 | 1.2M | 0% | +$0 | 1.61 | |
| Cormorant Asset Management Lp | $31.63M | 3.71 | 1.07M | -11.71% | -$4.2M | 1.47 | |
| Great Point Partners | $26.25M | 3.08 | 887,690 | -14.46% | -$4.44M | 4.4 | |
| Driehaus Capital Management LLC | $23.51M | 2.76 | 794,992 | -24.87% | -$7.78M | 0.23 | |
| BlackRock | $20.99M | 2.46 | 709,752 | -2.43% | -$523,448.15 | <0.0001 | |
| The Vanguard Group | $19.88M | 2.33 | 672,275 | +7.25% | +$1.34M | <0.0001 | |
| OrbiMed | $16.72M | 1.96 | 565,374 | -25.31% | -$5.66M | 0.13 | |
| Fidelity Investments | $15.89M | 1.87 | 537,530 | +<0.01% | +$1,301.08 | <0.01 | |
| Eventide Asset Management | $13.17M | 1.55 | 445,500 | +3,558.24% | +$12.81M | 0.21 | |
| Octagon Capital Advisors LP | $11.94M | 1.4 | 403,685 | 0% | +$0 | 0.07 | |
| Point72 Asset Management | $11.82M | 1.39 | 399,824 | -9.43% | -$1.23M | 0.02 | |
| Ikarian Capital LLC | $10.88M | 1.28 | 367,965 | New | +$10.88M | 1.5 | |
| Geode Capital Management | $8.33M | 0.98 | 281,760 | +1.76% | +$143,875.78 | <0.01 | |
| Ensign Peak Advisors Inc | $7.75M | 0.91 | 262,257 | +114.51% | +$4.14M | 0.01 | |
| State Street | $6.8M | 0.8 | 229,986 | +7.46% | +$471,907.63 | <0.0001 | |
| GHOST TREE CAPITAL LLC | $6.65M | 0.78 | 225,000 | +7.14% | +$443,550.00 | 0.09 | |
| Woodline Partners LP | $5.91M | 0.69 | 200,000 | New | +$5.91M | 0.05 | |
| Northern Trust | $2.91M | 0.34 | 98,559 | -0.97% | -$28,623.76 | <0.0001 | |
| Boothbay Fund Management LLC | $2.89M | 0.34 | 97,842 | New | +$2.89M | 0.09 | |
| Nantahala Capital Management Llc | $2.7M | 0.32 | 91,188 | 0% | +$0 | 0.13 | |
| Millennium Management LLC | $1.85M | 0.22 | 62,555 | New | +$1.85M | <0.01 | |
| Walleye Capital | $1.61M | 0.19 | 54,520 | New | +$1.61M | <0.01 | |
| Eversept Partners LP | $1.6M | 0.19 | 54,150 | +7.78% | +$115,559.60 | 0.12 | |
| Nan Fung Group | $1.42M | 0.17 | 47,936 | 0% | +$0 | 1.54 | |
| SEB | $1.31M | 0.15 | 44,320 | -12.87% | -$193,565.16 | 0.01 | |
| Alger | $1.29M | 0.15 | 43,790 | +20.05% | +$216,215.79 | 0.01 | |
| Nuveen | $1.18M | 0.14 | 40,047 | 0% | +$0 | <0.0001 | |
| Charles Schwab | $915,428.00 | 0.11 | 30,958 | +4.79% | +$41,871.12 | <0.0001 | |
| BNY Mellon | $818,025.00 | 0.1 | 27,664 | -24.33% | -$262,995.75 | <0.0001 | |
| Morgan Stanley | $777,189.00 | 0.09 | 26,283 | -25.02% | -$259,299.56 | <0.0001 | |
| Shay Capital Llc | $727,067.00 | 0.09 | 24,588 | New | +$727,067.00 | 0.11 | |
| Two Sigma | $677,537.00 | 0.08 | 22,913 | +134.76% | +$388,933.97 | <0.01 | |
| Prelude Capital | $611,655.00 | 0.07 | 20,685 | New | +$611,655.00 | 0.05 | |
| Alps Advisors Inc | $577,177.00 | 0.07 | 19,519 | +4.28% | +$23,685.58 | <0.01 | |
| Parkwood LLC | $524,000.00 | 0.06 | 17,728 | +12.3% | +$57,401.17 | 0.06 | |
| D. E. Shaw & Co. | $510,526.00 | 0.06 | 17,265 | New | +$510,526.00 | <0.0001 | |
| Dimensional Fund Advisors | $442,279.00 | 0.05 | 14,957 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $432,363.00 | 0.05 | 14,622 | +3.29% | +$13,749.75 | <0.0001 | |
| AllianceBernstein | $387,367.00 | 0.05 | 13,100 | 0% | +$0 | <0.0001 | |
| PDT Partners | $374,948.00 | 0.04 | 12,680 | New | +$374,948.00 | 0.03 | |
| UBS | $332,278.00 | 0.04 | 11,237 | -8.2% | -$29,688.27 | <0.0001 | |
| Jane Street Capital | $333,076.00 | 0.04 | 11,264 | -14.05% | -$54,467.86 | <0.0001 | |
| Jump Financial Llc | $283,872.00 | 0.03 | 9,600 | New | +$283,872.00 | <0.01 | |
| Bank of America | $263,676.00 | 0.03 | 8,917 | -60.72% | -$407,504.65 | <0.0001 | |
| Barclays | $233,000.00 | 0.03 | 7,872 | -48.86% | -$222,640.50 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.